https://alzheon.com/alzheon-emerges-from-stealth-hunts-for-alzheimers-castoffs/ 2019-09-23T16:10:55+00:00 monthly 0.6 https://alzheon.com/alzheimers-team-tackles-a-daunting-rd-field-with-a-new-game-plan/ 2019-09-23T16:10:55+00:00 monthly 0.6 https://alzheon.com/alzheon-launches-with-veteran-team-and-funding-to-accelerate-drug-development-in-alzheimers-disease-and-other-neurodegenerative-disorders/ 2019-09-23T16:10:55+00:00 monthly 0.6 https://alzheon.com/startup-finds-hope-in-second-look-at-failed-alzheimers-drugs/ 2019-09-23T16:10:55+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-nomination-by-industry-leaders-for-the-most-promising-company-competition-at-the-personalized-medicine-world-conferencealzheon-announces-notice-of-allowance-for-u-s-patent-for-its-le/ 2024-05-14T17:07:38+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-notice-of-allowance-for-u-s-patent-for-its-lead-drug-candidate-alz-801-in-clinical-development-for-alzheimers-disease/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-patent-issuance-in-japan-for-alz-801-in-development-for-alzheimers-disease/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/six-drugs-that-could-change-the-world/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/alzheon-appoints-david-nikodem-ph-d-to-board-of-directors/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-patent-allowance-in-europe-for-alz-801-in-development-for-alzheimers-disease/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-phase-1-results-of-alz-801-a-first-in-class-inhibitor-of-amyloid-formation-and-neurotoxicity-for-alzheimers-disease/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/lexingtons-alzheon-gives-its-own-alzheimers-news-to-rival-biogens/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/analyses-of-tramiprosate-phase-3-trials-show-improvement-in-cognition-and-function-in-apoe4-positive-alzheimers-disease-subjects-reaching-4-point-improvement-from-placebo-on-adas-cog-in-homoz/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/alzheimers-startup-alzheon-bags-10m-and-beats-a-path-to-phase-iii/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/alzheon-gets-10m-to-take-castoff-alzheimers-drug-into-pivotal-test/ 2024-08-02T12:53:28+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-10-million-series-a-financing/ 2019-09-23T16:10:54+00:00 monthly 0.6 https://alzheon.com/alzheon-establishes-new-corporate-headquarters/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-efficacy-analyses-prior-tramiprosate-phase-3-studies-showing-clinically-meaningful-benefits-key-clinical-endpoints-alzheimers-disease-patients-apoe-copy/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/cognitive-and-functional-efficacy-of-tramiprosate-in-apoe4-patients-with-mild-to-moderate-alzheimers-disease-subgroup-analyses-of-the-phase-3-north-american-and-european-trials/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-initiation-of-clinical-studies-with-alz%e2%80%90801-bridging-to-pivotal-phase-3-study-in-alzheimers-disease/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-efficacy-outcomes-from-two-prior-tramiprosate-phase-3-studies/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-presentations-at-two-upcoming-investor-conferences/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/alzheon-highlighted-one-top-20-life-science-startups-watch-u-s/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-efficacy-analyses-prior-tramiprosate-phase-3-studies-showing-clinically-meaningful-benefits-key-clinical-endpoints-alzheimers-disease-patients-apoe/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/tramiprosate-an-oral-amyloid-anti-aggregation-agent-shows-robust-cognitive-efficacy-in-apoe44-homozygous-ad-patients-efficacy-and-safety-analyses-from-two-phase-3-trials/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/efficacy-of-tramiprosate-in-apoe4-heterozygous-patients-with-mild-to-moderate-ad-combined-sub-group-analyses-from-two-phase-3-trials/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/phase-1-development-alz-801-novel-beta-amyloid-anti-aggregation-prodrug-tramiprosate-improved-drug-properties-supporting-bridging-phase-3-program/ 2019-09-23T16:10:53+00:00 monthly 0.6 https://alzheon.com/clinically-meaningful-cognitive-functional-improvements-tramiprosate-alzheimers-disease-ad-patients-apoe44-genotype-subgroup-analyses-two-phase-3-studies/ 2019-09-23T16:10:52+00:00 monthly 0.6 https://alzheon.com/alzheon-presents-positive-results-of-alz-801-clinical-studies-that-lead-to-advancement-to-pivotal-phase-3-study-in-alzheimers-patients-with-apoe44-homozygous-genotype/ 2019-09-23T16:10:52+00:00 monthly 0.6 https://alzheon.com/alzheimers-biotech-alzheon-to-move-once-failed-drug-into-new-phiii/ 2024-07-10T18:05:18+00:00 monthly 0.6 https://alzheon.com/little-known-drug-company-answer-alzheimers-patients/ 2019-09-23T16:10:52+00:00 monthly 0.6 https://alzheon.com/alzheon-publishes-new-analyses-from-phase-3-studies-showing-clinical-benefit-of-tramiprosate-in-alzheimers-patients-who-are-carriers-of-apoe4-the-major-genetic-risk-factor-in-up-to-65-percen/ 2019-09-23T16:10:52+00:00 monthly 0.6 https://alzheon.com/gene-dose-effect-alzheons-alz-801-drug-targeting-alzheimers-disease/ 2019-09-23T16:10:52+00:00 monthly 0.6 https://alzheon.com/clinical-benefits-tramiprosate-alzheimers-disease-associated-higher-number-apoe4-alleles-apoe4-gene-dose-effect/ 2019-09-23T16:10:50+00:00 monthly 0.6 https://alzheon.com/phase-1-program-alz-801-novel-prodrug-tramiprosate-improved-tolerability-supports-bridging-upcoming-phase-3-program/ 2019-09-23T16:10:50+00:00 monthly 0.6 https://alzheon.com/tramiprosate-efficacy-apoe4-homozygous-subjects-ad-larger-effects-mild-patient-subgroups/ 2019-09-23T16:10:50+00:00 monthly 0.6 https://alzheon.com/alz-801-brain-penetration-pkpd-analyses-clinical-dose-projection-form-basis-confirmatory-phase-3-study-alzheimers-disease/ 2019-09-23T16:10:50+00:00 monthly 0.6 https://alzheon.com/elucidating-a%ce%b242-anti-aggregation-mechanism-action-tramiprosate-alzheimers-disease-integrating-molecular-analytical-methods-pharmacokinetic-clinical-data/ 2019-09-23T16:10:49+00:00 monthly 0.6 https://alzheon.com/alzheon-scientists-discover-novel-therapeutic-mechanism-inhibition-formation-toxic-beta-amyloid-oligomers-key-driver-alzheimers-disease-pathogenesis/ 2024-08-05T22:26:31+00:00 monthly 0.6 https://alzheon.com/insights-discovery-clinical-efficacy-support-new-class-therapeutics-alzheimers-disease/ 2019-09-23T16:10:49+00:00 monthly 0.6 https://alzheon.com/alzheon-publishes-new-analyses-showing-clinical-benefit-tramiprosate-apoe44-homozygous-patients-mild-stage-alzheimers-disease-clinical-effects-suggest-disease-modification-p/ 2024-08-02T15:26:03+00:00 monthly 0.6 https://alzheon.com/clinical-effects-tramiprosate-apoe44-homozygous-patients-mild-alzheimers-disease-suggest-disease-modification-potential/ 2019-09-23T16:10:49+00:00 monthly 0.6 https://alzheon.com/alzheon-says-data-backs-potential-of-alzheimers-candidate/ 2019-09-23T16:10:49+00:00 monthly 0.6 https://alzheon.com/alz-801-mechanism-action-stoichiometry-beta-amyloid-anti-oligomer-effect-pkpd-clinical-dose-selection-confirmatory-phase-3-program-alzheimers-disease/ 2019-09-23T16:10:49+00:00 monthly 0.6 https://alzheon.com/alzheon-updates-precision-medicine-approach-treating-ad/ 2019-09-23T16:10:48+00:00 monthly 0.6 https://alzheon.com/clinical-pharmacokinetics-safety-alz-801-novel-prodrug-tramiprosate-development-treatment-alzheimers-disease/ 2019-09-23T16:10:48+00:00 monthly 0.6 https://alzheon.com/alzheon-publishes-clinical-results-demonstrate-safety-profile-efficacy-potential-alz-801-orally-available-precision-medicine-treat-alzheimers-disease/ 2024-08-05T23:12:51+00:00 monthly 0.6 https://alzheon.com/fda-grants-fast-track-designation-to-alzheons-alz-801-development-program-for-the-treatment-of-alzheimers-disease/ 2024-08-05T21:32:43+00:00 monthly 0.6 https://alzheon.com/clinical-effects-tramiprosate-apoe4-homozygotes-mild-moderate-alzheimers-disease-ad-sustained-130-weeks-results-phase-3-extension-study/ 2019-09-23T16:10:48+00:00 monthly 0.6 https://alzheon.com/alzheon-presents-new-findings-in-apoe4-4-homozygous-patients-with-mild-alzheimers-disease-further-supporting-precision-medicine-approach-and-planned-confirmatory-clinical-trial-with-alz-801/ 2024-08-05T19:03:03+00:00 monthly 0.6 https://alzheon.com/clinical-benefits-of-oral-tramiprosate-in-apoe4-4-homozygotes-with-mild-alzheimers-disease-ad-responder-analyses-from-the-phase-3-north-american-trial/ 2019-09-23T16:10:47+00:00 monthly 0.6 https://alzheon.com/discovery-of-an-endogenous-metabolite-of-tramiprosate-and-its-prodrug-alz-801-that-inhibits-beta-amyloid-oligomer-formation-in-human-brain/ 2024-06-19T20:49:25+00:00 monthly 0.6 https://alzheon.com/alzheon-appoints-former-ivax-president-neil-flanzraich-jd-as-vice-chairman-of-board-of-directors/ 2024-08-05T18:56:26+00:00 monthly 0.6 https://alzheon.com/alzheon-scientists-discover-endogenous-substance-in-human-brain-that-inhibits-formation-of-toxic-beta-amyloid-oligomers-key-driver-of-alzheimers-disease/ 2024-08-02T15:00:26+00:00 monthly 0.6 https://alzheon.com/clinical-effects-of-oral-tramiprosate-in-apoe4-4-homozygotes-with-mild-alzheimers-disease-ad-responder-analyses-of-cognitive-and-functional-outcomes/ 2019-09-23T16:10:47+00:00 monthly 0.6 https://alzheon.com/apoe4-4-early-to-mild-ad-subjects-show-high-rates-of-hippocampal-atrophy-and-cognitive-decline-in-adni-1-and-tramiprosate-datasets/ 2019-09-23T16:10:47+00:00 monthly 0.6 https://alzheon.com/exponential-martin-tolar/ 2019-09-23T16:10:46+00:00 monthly 0.6 https://alzheon.com/alzheon-presents-data-on-the-discovery-of-3-spa-an-endogenous-substance-in-the-human-brain-at-the-alzheimers-association-international-conference/ 2024-08-02T14:30:48+00:00 monthly 0.6 https://alzheon.com/generation-bold-interview-with-alzheon-ceo-martin-tolar/ 2024-08-26T15:04:01+00:00 monthly 0.6 https://alzheon.com/take-a-pill-for-it-approach-to-alzheimers-disease/ 2024-08-26T15:04:59+00:00 monthly 0.6 https://alzheon.com/alzheon-publication-defines-new-path-for-2nd-generation-anti-amyloid-drugs-for-alzheimers-disease/ 2024-08-02T17:03:06+00:00 monthly 0.6 https://alzheon.com/alzheon-gets-closer-to-alzheimers-drug-treatment/ 2024-08-09T15:11:21+00:00 monthly 0.6 https://alzheon.com/apoe4-4-subjects-with-early-alzheimers-disease-show-accelerated-loss-of-cortical-thickness-and-cognitive-decline-compared-to-apoe3-3-subjects/ 2019-11-27T21:57:28+00:00 monthly 0.6 https://alzheon.com/the-path-forward-in-alzheimers-disease-therapeutics-reevaluating-the-amyloid-cascade-hypothesis/ 2024-06-19T20:32:55+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-appointments-of-noel-dunn-jordan-heller-and-diane-jorkasky-md-to-board-of-directors/ 2024-08-05T17:46:40+00:00 monthly 0.6 https://alzheon.com/neurodegenerative-treatments-build-to-a-tipping-point/ 2020-08-22T00:16:49+00:00 monthly 0.6 https://alzheon.com/is-targeting-oligomers-in-apoe4-homozygotes-the-path-forward-in-alzheimers-disease/ 2020-08-22T00:16:04+00:00 monthly 0.6 https://alzheon.com/targeting-amyloid-oligomers-for-alzheimers-research/ 2020-08-22T00:13:44+00:00 monthly 0.6 https://alzheon.com/aducanumab-gantenerumab-ban2401-and-alz-801-the-first-wave-of-amyloid-targeting-drugs-for-alzheimers-disease-with-potential-for-near-term-approval/ 2024-06-19T22:00:43+00:00 monthly 0.6 https://alzheon.com/peer-reviewed-scientific-publication-profiles-first-wave-of-disease-modifying-alzheimers-treatments-with-potential-for-near-term-approval-aducanumab-gantenerumab-ban2401-and-alz-801/ 2024-08-12T14:15:30+00:00 monthly 0.6 https://alzheon.com/alzheon-awarded-47-million-grant-from-u-s-national-institute-on-aging-for-phase-3-clinical-study-of-alz-801-an-oral-treatment-for-alzheimers-disease/ 2024-08-05T23:24:36+00:00 monthly 0.6 https://alzheon.com/nia-backs-alzheons-phase-iii-alzheimers-trial-with-47-million-grant/ 2020-08-22T01:40:29+00:00 monthly 0.6 https://alzheon.com/boost-for-alzheons-targeted-alzheimers-candidate/ 2020-08-22T01:39:34+00:00 monthly 0.6 https://alzheon.com/alzheon-receives-47m-nih-grant-funding-its-phase-iii-alzheimers-study/ 2020-08-22T01:04:15+00:00 monthly 0.6 https://alzheon.com/biotechs-tap-growing-u-s-government-support-for-alzheimers-research/ 2021-08-19T14:20:44+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-dosing-of-first-patient-in-alz-801-phase-2-biomarker-study-in-apoe4-carriers-with-early-alzheimers-disease/ 2024-08-26T14:55:47+00:00 monthly 0.6 https://alzheon.com/breakthrough-in-the-race-for-an-alzheimers-drug/ 2024-08-09T15:10:21+00:00 monthly 0.6 https://alzheon.com/potential-for-an-alzheimers-treatment-appears-to-be-closer-than-ever/ 2020-12-07T14:44:16+00:00 monthly 0.6 https://alzheon.com/apoe-%ce%b54-%ce%b54-homozygotes-with-early-alzheimers-disease-show-accelerated-hippocampal-atrophy-and-cortical-thinning-that-correlates-with-cognitive-decline/ 2024-08-09T15:39:48+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-new-research-showing-accelerated-hippocampus-atrophy-in-apoe4-4-patients-with-early-alzheimers-disease/ 2024-08-26T15:00:13+00:00 monthly 0.6 https://alzheon.com/alzheon-ceo-presents-overview-of-oral-anti-amyloid-alz-801-phase-3-program-at-9th-neurodegenerative-drug-development-summit/ 2024-08-05T23:43:03+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-at-h-c-wainwright-global-life-sciences-conference/ 2024-08-26T15:02:06+00:00 monthly 0.6 https://alzheon.com/new-drug-approval-could-be-on-horizon-for-alzheimers-after-17-year-drought/ 2024-07-29T19:57:00+00:00 monthly 0.6 https://alzheon.com/alzheon-partners-with-czech-institute-of-organic-chemistry-and-biochemistry-to-develop-first-alzheimers-diagnostic-assay-for-measuring-neurotoxic-beta-amyloid-oligomers-in-human-brain/ 2024-08-26T15:01:41+00:00 monthly 0.6 https://alzheon.com/biotech-startup-alzheon-strikes-deal-to-develop-alzheimers-test/ 2024-07-29T19:34:39+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-first-patient-dosed-in-apolloe4-phase-3-trial-of-oral-alz-801-in-patients-with-early-alzheimers-disease/ 2024-08-26T14:57:03+00:00 monthly 0.6 https://alzheon.com/fda-approval-of-debated-alzheimers-drug-is-tremendous-for-society/ 2024-08-05T22:57:02+00:00 monthly 0.6 https://alzheon.com/here-are-the-9-biggest-biotech-winners-after-the-fda-took-an-entirely-new-approach-to-approve-biogens-alzheimers-drug/ 2024-07-29T19:37:37+00:00 monthly 0.6 https://alzheon.com/alzheimers-is-open-for-business-controversial-fda-approval-could-pave-the-way-for-future-drugs/ 2024-07-29T19:23:18+00:00 monthly 0.6 https://alzheon.com/investor-interest-in-alzheimers-changed-on-the-dime-following-fdas-decision-on-biogens-aducanumab/ 2024-07-29T19:38:07+00:00 monthly 0.6 https://alzheon.com/treating-alzheimers-disease-alzheon-moves-forward-with-trials-for-new-medication/ 2024-08-05T22:47:48+00:00 monthly 0.6 https://alzheon.com/neurotoxic-soluble-amyloid-oligomers-drive-alzheimers-pathogenesis-and-represent-a-clinically-validated-target-for-slowing-disease-progression/ 2024-08-09T15:48:15+00:00 monthly 0.6 https://alzheon.com/peer-reviewed-scientific-publication-demonstrates-central-role-of-neurotoxic-soluble-amyloid-oligomers-in-driving-alzheimers-pathogenesis/ 2024-08-12T14:14:03+00:00 monthly 0.6 https://alzheon.com/alzheon-completes-patient-enrollment-in-phase-2-biomarker-trial-of-alz-801-oral-tablet-in-apoe4-carriers-with-alzheimers-disease/ 2024-08-05T23:54:22+00:00 monthly 0.6 https://alzheon.com/paper-highlights-role-of-neurotoxic-soluble-amyloid-oligomers-in-alzheimers-pathogenesis/ 2021-06-25T19:19:06+00:00 monthly 0.6 https://alzheon.com/generation-bold-alzheon-announces-first-patient-dosed-in-phase-3-trial/ 2024-08-05T22:53:38+00:00 monthly 0.6 https://alzheon.com/alz-801-martin-tolar-faces-one-of-the-greatest-czech-successes/ 2024-05-14T18:09:19+00:00 monthly 0.6 https://alzheon.com/alzheon-appoints-adem-albayrak-as-head-of-operations-and-earvin-liang-phd-as-vice-president-of-clinical-development/ 2024-08-26T15:01:08+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-at-h-c-wainwright-annual-global-investment-conference-on-september-13-2021/ 2024-08-12T13:32:26+00:00 monthly 0.6 https://alzheon.com/martin-tolar-of-alzheon-receives-the-czech-laurels-award-from-the-chamber-of-commerce-of-the-czech-republic/ 2021-10-20T23:25:19+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-new-data-from-ongoing-phase-2-biomarker-trial-of-alz-801-oral-tablet-at-clinical-trials-in-alzheimers-disease-ctad-conference/ 2024-08-12T14:06:16+00:00 monthly 0.6 https://alzheon.com/big-pharma-abandoned-alzheimers-this-good-unicorn-stayed-and-found-a-potential-cure/ 2021-11-09T23:42:03+00:00 monthly 0.6 https://alzheon.com/anti-amyloid-drugs-the-failure-of-success/ 2022-01-04T18:37:06+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-at-h-c-wainwright-bioconnect-conference-on-january-10-2022/ 2024-08-12T13:33:43+00:00 monthly 0.6 https://alzheon.com/alzheon-reports-industry-leading-disease-modifying-effects-from-phase-2-biomarker-trial-of-oral-tablet-alz-801-valiltramiprosate-in-patients-with-early-alzheimers-disease/ 2024-08-12T13:05:12+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-alz-801-at-ad-pd-and-ndds-scientific-conferences/ 2024-08-12T13:23:49+00:00 monthly 0.6 https://alzheon.com/2022-new-alzheon-leadership-appointments/ 2024-08-26T14:49:27+00:00 monthly 0.6 https://alzheon.com/alzheimers-drug-developer-alzheon-secures-50-million/ 2023-05-01T12:55:43+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-closing-of-oversubscribed-50-million-series-d-financing-round/ 2024-08-26T14:54:53+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-alz-801-at-4th-international-trisomy-21-research-conference/ 2024-08-12T13:18:21+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-industry-leading-phase-2-biomarker-and-clinical-data-with-alz-801-valiltramiprosate-oral-tablet-at-2022-alzheimers-association-international-conference/ 2024-08-12T14:03:18+00:00 monthly 0.6 https://alzheon.com/alzheon-appoints-glenn-pauly-as-head-of-commercial/ 2024-08-05T23:22:39+00:00 monthly 0.6 https://alzheon.com/alzheon-reports-industry-leading-biomarker-brain-preservation-and-clinical-effects-following-12-months-of-treatment-in-phase-2-trial-of-oral-alz-801-valiltramiprosate-in-patients-with-early-alzheim/ 2024-08-06T00:01:25+00:00 monthly 0.6 https://alzheon.com/alzheon-biomarker-trial-brings-insight-to-stalled-treatment-space/ 2022-10-02T20:55:56+00:00 monthly 0.6 https://alzheon.com/alzheons-pill-for-alzheimers-recruits-for-clinical-trials/ 2022-11-07T23:32:37+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-industry-leading-biomarker-brain-preservation-and-clinical-effects-with-oral-alz-801-valiltramiprosate-at-15th-annual-clinical-trials-in-alzheimers-disease-conference/ 2024-08-12T13:59:56+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-early-completion-of-enrollment-of-apolloe4-phase-3-clinical-trial-evaluating-oral-alz-801-valiltramiprosate-in-apoe4-4-homozygotes-with-early-alzheimers-disease/ 2024-08-26T14:56:30+00:00 monthly 0.6 https://alzheon.com/biotech-and-business-development-leader-wendy-nelson-on-living-with-the-apoe4-gene/ 2023-01-20T16:31:56+00:00 monthly 0.6 https://alzheon.com/i-interview-dr-martin-tolar-founder-ceo-and-president-of-alzheon-on-the-phase-3-trail-going-on-right-now/ 2023-02-16T17:37:20+00:00 monthly 0.6 https://alzheon.com/its-night-and-day-biogens-new-alzheimers-drug-may-spur-more-investment-in-fighting-the-disease/ 2024-08-02T12:55:07+00:00 monthly 0.6 https://alzheon.com/investment-reports-article-martin-tolar-ceo-alzheon/ 2023-04-16T16:18:58+00:00 monthly 0.6 https://alzheon.com/why-lecanemabs-success-spells-the-revival-of-small-molecule-alzheimers-treatments/ 2024-05-15T20:38:27+00:00 monthly 0.6 https://alzheon.com/the-new-era-of-life-sciences/ 2024-08-02T13:47:38+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-biomarker-brain-preservation-and-clinical-effects-of-oral-tablet-alz-801-valiltramiprosate-at-upcoming-ad-pd-2023-conference-in-gothenburg-sweden/ 2024-08-12T13:51:50+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-baseline-imaging-characteristics-from-ongoing-apolloe4-phase-3-trial-of-oral-tablet-alz-801-valiltramiprosate-and-results-of-phase-2-biomarker-study-at-american-academy-of-neurolo/ 2024-08-12T13:50:32+00:00 monthly 0.6 https://alzheon.com/oral-anti-amyloid-shows-disease-modifying-potential-phase-2-data/ 2023-05-03T16:05:29+00:00 monthly 0.6 https://alzheon.com/aan-2023-alz-801-for-alzheimers-found-to-improve-cognition-in-trial/ 2023-05-03T15:24:17+00:00 monthly 0.6 https://alzheon.com/eli-lillys-donanemab-the-anti-amyloid-saga-continues/ 2023-07-31T19:59:29+00:00 monthly 0.6 https://alzheon.com/understanding-patient-characteristics-of-phase-3-apolloe4-trial-of-alz-801-in-alzheimer-disease-john-hey-phd/ 2023-05-31T22:05:53+00:00 monthly 0.6 https://alzheon.com/science-behind-the-drug-that-may-stop-alzheimers-disease-in-its-tracks/ 2023-07-17T17:26:16+00:00 monthly 0.6 https://alzheon.com/alz-801-aims-to-preserve-memories-save-lives-an-exclusive-interview-with-dr-martin-tolar/ 2023-07-27T21:26:57+00:00 monthly 0.6 https://alzheon.com/unprecedented-reduction-in-key-alzheimers-biomarker-for-patients-treated-with-alz-801/ 2023-07-28T14:07:13+00:00 monthly 0.6 https://alzheon.com/part-1-the-role-of-apoe-genotyping-in-alzheimers-disease-risk-stratification/ 2023-07-20T14:29:35+00:00 monthly 0.6 https://alzheon.com/part-2-apoe-genotyping-in-clinical-practice-pros-and-cons/ 2023-07-20T14:30:08+00:00 monthly 0.6 https://alzheon.com/advances-in-ad-treatments/ 2023-07-20T14:28:14+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-baseline-imaging-characteristics-from-ongoing-apolloe4-phase-3-trial-of-oral-tablet-alz-801-valiltramiprosate-and-positive-biomarker-clinical-correlations-from-phase-2-biomarker-s/ 2024-08-12T13:43:10+00:00 monthly 0.6 https://alzheon.com/venture-capitalists-fund-new-generation-of-alzheimers-drugs/ 2024-06-06T21:58:07+00:00 monthly 0.6 https://alzheon.com/aaic-a-pill-to-slow-down-alzheimers-is-about-two-years-away/ 2023-07-18T14:41:12+00:00 monthly 0.6 https://alzheon.com/alzheon-reports-industry-leading-biomarker-brain-preservation-and-clinical-benefits-following-24-months-of-treatment-in-phase-2-trial-of-oral-alz-801-valiltramiprosate-in-patients-with-early-alzhei/ 2024-08-05T23:59:29+00:00 monthly 0.6 https://alzheon.com/alzheimer-agent-alz-801-improves-cognition-reduces-relevant-biomarker-levels-in-2-year-analysis/ 2023-09-21T14:37:23+00:00 monthly 0.6 https://alzheon.com/alz-801-for-2-years-seen-to-sustain-cognition-in-early-alzheimers/ 2023-10-02T15:49:22+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-pivotal-program-of-oral-alz-801-valiltramiprosate-at-singularity-conference-goldman-sachs-alzheimers-disease-day-and-bio-investor-forum/ 2024-08-12T14:07:38+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-biomarker-brain-preservation-and-clinical-results-from-pivotal-program-of-oral-alz-801-valiltramiprosate-at-16th-annual-clinical-trials-in-alzheimers-disease-conference/ 2024-08-12T13:52:46+00:00 monthly 0.6 https://alzheon.com/alzheon-ceo-dr-martin-tolar-to-discuss-positive-results-from-phase-2-biomarker-study-and-upcoming-readout-from-pivotal-apolloe4-phase-3-study-evaluating-oral-alz-801-valiltramiprosate-at-truist-secur/ 2024-08-05T23:28:01+00:00 monthly 0.6 https://alzheon.com/alzheon-promotes-glenn-e-pauly-to-chief-commercial-officer-and-strengthens-commercial-organization-with-new-executive-appointments-to-lead-planned-u-s-commercial-launch-of-oral-alz-801-valiltramipro/ 2024-08-05T23:57:04+00:00 monthly 0.6 https://alzheon.com/alzheon-ceo-dr-martin-tolar-awarded-eliska-and-zdenek-strmiska-award-from-alzheimers-foundation-for-significant-contribution-towards-research-and-treatment-of-alzheimers-disease-an/ 2024-08-05T23:26:13+00:00 monthly 0.6 https://alzheon.com/alzheon-ceo-dr-martin-tolar-to-present-alz-801-valiltramiprosate-investigational-oral-alzheimers-treatment-program-at-nobel-forum-at-karolinska-institute-in-stockholm-sweden/ 2024-08-05T23:40:59+00:00 monthly 0.6 https://alzheon.com/investment-reports-article-martin-tolar-ceo-alzheon-2024/ 2024-06-03T18:42:41+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-biomarker-brain-preservation-and-clinical-results-from-pivotal-program-of-oral-alz-801-valiltramiprosate-at-international-conference-on-alzheimers-and-parkinsons/ 2024-08-12T13:58:01+00:00 monthly 0.6 https://alzheon.com/the-single-toxin-origin-of-alzheimers-disease-and-other-neurodegenerative-disorders-enables-targeted-approach-to-treatment-and-prevention/ 2024-06-19T20:17:21+00:00 monthly 0.6 https://alzheon.com/peer-reviewed-scientific-publication-proposes-unifying-single-toxin-theory-of-brain-neurodegeneration-that-identifies-new-drug-targets-and-treatments-for-alzheimers-disease-and-other-neurodeg/ 2024-08-12T14:16:59+00:00 monthly 0.6 https://alzheon.com/beginning-a-new-era-of-precision-alzheimers-therapeutics/ 2024-06-03T18:44:54+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-that-united-states-federal-circuit-affirmed-decision-of-u-s-patent-office-invalidating-risen-suzhou-pharmaceutical-technology-co-ltd-s-patent-on-isotopically-enriched-f/ 2024-08-26T15:00:41+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-first-patient-dosed-in-long-term-extension-of-apolloe4-phase-3-trial-of-oral-alz-801-valiltramiprosate-and-launches-52-week-extension-of-phase-2-biomarker-trial-in-patients-with-earl/ 2024-08-26T14:57:45+00:00 monthly 0.6 https://alzheon.com/breakthroughs-in-alzheimer-research-pave-way-for-new-era-of-treatment-martin-tolar-md-phd/ 2024-06-26T18:05:46+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-appointment-of-renowned-biopharma-executive-gino-santini-to-board-of-directors/ 2024-08-26T14:54:16+00:00 monthly 0.6 https://alzheon.com/100-million-series-e/ 2024-08-26T14:49:53+00:00 monthly 0.6 https://alzheon.com/with-fresh-100m-alzheon-lays-out-strategy-for-alzheimers-approval-next-year/ 2024-06-14T16:25:50+00:00 monthly 0.6 https://alzheon.com/alzheimers-drug-developer-alzheon-closes-100m-series-e-financing/ 2024-06-14T16:13:01+00:00 monthly 0.6 https://alzheon.com/effects-of-oral-alz-801-valiltramiprosate-on-plasma-biomarkers-brain-hippocampal-volume-and-cognition-results-of-2-year-single-arm-open-label-phase-2-trial-in-apoe4-carriers-with-early-alzheimer/ 2024-06-20T21:34:20+00:00 monthly 0.6 https://alzheon.com/analysis-of-cerebrospinal-fluid-plasma-%ce%b2-amyloid-biomarkers-and-cognition-from-a-2-year-phase-2-trial-evaluating-oral-alz-801-valiltramiprosate-in-apoe4-carriers-with-early-alzheimers/ 2024-06-20T21:34:11+00:00 monthly 0.6 https://alzheon.com/alzheon-nabs-100m-in-series-e-to-advance-oral-alzheimers-drug/ 2024-06-26T19:07:42+00:00 monthly 0.6 https://alzheon.com/two-peer-reviewed-scientific-publications-describe-fluid-biomarker-brain-preservation-and-clinical-benefits-following-2-years-of-treatment-in-phase-2-trial-evaluating-oral-alz-801-valiltramiprosate-i/ 2024-08-26T15:05:55+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-phase-2-biomarker-trial-results-and-baseline-characteristics-from-apolloe4-phase-3-trial-of-oral-alz-801-valiltramiprosate-in-patients-with-early-alzheimers-disease-at-alzh/ 2024-07-19T14:15:31+00:00 monthly 0.6 https://alzheon.com/apolloe4-phase-3-study-of-oral-alz-801-valiltramiprosate-in-apoe-%ce%b54-%ce%b54-homozygotes-with-early-alzheimers-disease-trial-design-and-baseline-characteristics/ 2025-04-13T19:47:38+00:00 monthly 0.6 https://alzheon.com/new-peer-reviewed-scientific-publication-describes-study-design-and-baseline-characteristics-from-apolloe4-phase-3-trial-of-oral-alz-801-valiltramiprosate-in-apoe4-4-homozygous-individuals-with-early/ 2025-02-20T23:54:55+00:00 monthly 0.6 https://alzheon.com/point-of-view-challenges-in-implementation-of-new-immunotherapies-for-alzheimers-disease/ 2025-04-13T20:00:29+00:00 monthly 0.6 https://alzheon.com/could-a-single-pill-crack-the-code-of-treating-alzheimers-disease/ 2025-01-04T20:43:38+00:00 monthly 0.6 https://alzheon.com/newsweek-investment-report-the-new-era-of-life-sciences-2025-edition-the-future-is-now/ 2025-05-19T18:02:04+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-appointment-of-renowned-investor-and-financial-executive-muneer-a-satter-to-board-of-directors/ 2025-01-03T14:31:33+00:00 monthly 0.6 https://alzheon.com/clinical-pharmacokinetics-of-oral-alz-801-valiltramiprosate-in-a-2-year-phase-2-trial-of-apoe4-carriers-with-early-alzheimers-disease/ 2025-04-13T20:04:23+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-two-new-scientific-papers-ahead-of-apolloe4-phase-3-trial-topline-symposium-at-adpd-conference-in-vienna/ 2025-02-23T18:49:33+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-results-from-pivotal-apolloe4-phase-3-trial-of-oral-valiltramiprosate-alz-801-at-dedicated-symposium-at-adpd-conference-in-vienna-on-april-1st-2025/ 2025-03-14T15:11:08+00:00 monthly 0.6 https://alzheon.com/topline-results-from-pivotal-apolloe4-phase-3-trial-of-oral-valiltramiprosate-alz-801-in-patients-with-early-alzheimers-disease-carrying-two-copies-of-apoe4-gene/ 2025-04-09T23:45:03+00:00 monthly 0.6 https://alzheon.com/polymorph-analysis-of-alz-801-valiltramiprosate-a-valine-conjugated-oral-prodrug-of-tramiprosate-in-late-stage-clinical-development-for-alzheimers-disease/ 2025-11-29T16:00:11+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-insights-into-oral-valiltramiprosate-alz-801-mode-of-action-and-clinical-efficacy-at-dedicated-symposium-at-alzheimers-association-international-conference-in-toronto/ 2025-07-14T16:32:56+00:00 monthly 0.6 https://alzheon.com/clinical-efficacy-safety-and-imaging-effects-of-oral-valiltramiprosate-in-apoe4-4-homozygotes-with-early-alzheimers-diseae-results-of-the-phase-iii-randomized-double-blind-placebo-contro/ 2025-11-25T20:44:54+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-peer-reviewed-scientific-publication-of-results-from-pivotal-apolloe4-phase-3-trial-of-oral-valiltramiprosate-alz-801-in-apoe4-4-homozygous-individuals-with-early-alzheimers/ 2025-10-12T17:56:35+00:00 monthly 0.6 https://alzheon.com/alzheons-oral-alzheimers-drug-shows-safety-and-promise-for-apoe4-4/ 2025-12-11T16:44:58+00:00 monthly 0.6 https://alzheon.com/an-alzheimers-pill-appears-to-protect-some-in-a-high-risk-population/ 2025-12-11T16:55:40+00:00 monthly 0.6 https://alzheon.com/alzheimers-pill-could-reduce-brain-decline-in-some-high-risk-patients-trial-suggests/ 2025-12-11T16:25:51+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-multiple-clinical-neuroimaging-and-modeling-results-for-oral-valiltramiprosate-alz-801-from-phase-2-and-3-studies-at-ctad-conference-in-san-diego-december-1-4-2025/ 2025-11-18T20:37:47+00:00 monthly 0.6 https://alzheon.com/hippocampal-atrophy-on-magnetic-resonance-imaging-as-a-surrogate-marker-for-clinical-benefit-and-neurodegeneration-in-early-symptomatic-alzheimers-disease-synthesis-of-evidence-from-observat/ 2025-12-11T17:05:05+00:00 monthly 0.6 https://alzheon.com/alzheon-announces-peer-reviewed-publication-providing-evidence-for-hippocampal-volume-as-surrogate-marker-for-clinical-benefit-and-neurodegeneration-in-early-alzheimers-disease/ 2026-04-05T23:02:34+00:00 monthly 0.6 https://alzheon.com/alzheon-reports-plasma-biomarker-results-from-phase-3-and-2-studies-of-valiltramiprosate-alz-801-validating-its-first-in-class-mechanism-of-action-and-underscoring-benefits-in-cognition-function-an/ 2026-04-05T23:00:00+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-clinical-imaging-and-fluid-biomarker-results-from-trials-with-oral-valiltramiprosate-alz-801-at-2026-ad-pd-conference-in-copenhagen-denmark/ 2026-04-05T22:58:50+00:00 monthly 0.6 https://alzheon.com/alzheon-advances-industry-leading-portfolio-of-oral-anti-amyloid-aggregation-inhibitors-with-first-subject-dosed-in-phase-1-of-alz-507-highlighting-potential-for-once-daily-administration-improved-s/ 2026-04-06T00:47:32+00:00 monthly 0.6 https://alzheon.com/alzheon-to-present-evidence-of-neurovascular-protection-from-trials-with-oral-valiltramiprosate-in-apoe4-4-alzheimers-patients-leading-to-reduced-brain-edema-and-microhemorrhage-risk-at-2026/ 2026-04-13T14:55:35+00:00 monthly 0.6